AstraZeneca settles SEROQUEL XR patent infringement litigation AstraZeneca today announced it has entered right into a settlement agreement in its U.S. The contract settles the patent infringement litigation filed by AstraZeneca pursuing Handa’s submission to the U.S. Meals and Medication Administration of an Abbreviated New Medication Software for a generic edition of SEROQUEL XR. Beneath the settlement contract, Handa will not dispute that both patents asserted by AstraZeneca in the U.S. Patent litigation are enforceable and valid. Within the contract, AstraZeneca offers granted Handa a permit to enter the U.S. November 2016 or earlier upon certain conditions marketplace with generic SEROQUEL XR on 1.Murdo Gordon provides been appointed president, U.S., and will report to Caforio. Gordon was most senior vice president recently, U.S. Oncology. Beatrice Cazala, executive vice president, Commercial Operations in charge of Global Commercialization, Europe and China, is in the process of transitioning to a new role within the company. By evolving our organization and expanding the functions of Giovanni and Charlie, Personally i think a lot more confident in the strength of my management team and our ability to take advantage of the most critical possibilities to build long-term sustainable development, stated Andreotti.